OverviewSuggest Edit

Zai Lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. The Company's vision is to address the largest unmet medical needs and transform patients’ lives around the world. Zai Lab takes a unique approach to combine both in-licensed products and internal R&D to achieve a rich pipeline.
TypePublic
Founded2013
HQCN
Websitezailaboratory.com

Latest Updates

Employees (est.) (Jul 2021)1,194
Job Openings31
Share Price (Jul 2021)$174(+2%)
Cybersecurity ratingCMore

Key People/Management at ZAI Lab

Samantha Du

Samantha Du

Founder, Chair and Chief Executive Officer
Yongjiang Hei

Yongjiang Hei

Chief Medical Officer, Oncology
Harald Reinhart

Harald Reinhart

Chief Medical Officer, Autoimmune and Infectious Diseases
F. Ty Edmondson

F. Ty Edmondson

Chief Legal Officer
William Liang

William Liang

Chief Commercial Officer, President, Greater China
Alan Sandler

Alan Sandler

President, Head of Global Development, Oncology
Show more

ZAI Lab Office Locations

ZAI Lab has offices in Suzhou Shi, Cambridge and Menlo Park
Suzhou Shi, CN
218 Xinghu St, Wuzhong Qu
Cambridge, MA, US
245 Main St 2nd floor
Menlo Park, CA, US
1440 O'Brien Dr ste a & c
Show all (6)

ZAI Lab Financials and Metrics

ZAI Lab Revenue

USD

Net income (FY, 2016)

(37.5m)

EBIT (FY, 2016)

(38.5m)

Market capitalization (14-Jul-2021)

16.5b

Closing stock price (14-Jul-2021)

174.0

Cash (31-Dec-2016)

83.9m
ZAI Lab's current market capitalization is $16.5 b.
USDFY, 2015FY, 2016

General and administrative expense

2.8m6.4m

R&D expense

13.6m32.1m

Operating expense total

13.6m32.1m

EBIT

(16.3m)(38.5m)
USDFY, 2015FY, 2016

Cash

13.2m83.9m

Total Assets

13.9m88.9m

Current Liabilities

3.9m5.2m

Non-Current Liabilities

62.0k778.0k
USDFY, 2015FY, 2016

Cash From Operating Activities

(11.5m)(32.2m)

Cash From Investing Activities

(738.0k)(2.7m)

Cash From Financing Activities

18.3m106.2m

Net Change in Cash

6.0m70.8m
USDFY, 2015

Financial Leverage

-0.8 x
Show all financial metrics

ZAI Lab Cybersecurity Score

Cybersecurity ratingPremium dataset

C

71/100

SecurityScorecard logo

ZAI Lab Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

ZAI Lab Online and Social Media Presence

Embed Graph

ZAI Lab News and Updates

MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

ROCKVILLE, MD, SHANGHAI and SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) --   MacroGenics (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal-antibody-based therapeutics for the treatment of cancer, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9…

Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

SHANGHAI, SAN FRANCISCO and ROCKVILLE, MD, June 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and MacroGenics (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monocl…

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China

SAN DIEGO and SHANGHAI and SAN FRANCISCO, June 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the...

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China

SAN DIEGO, SHANGHAI and SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the companies hav…

Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib

SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced dosing of the first patient in China in the registrational Phase 2 portion of TRIDENT-1 study of repotrectinib being con…

Zai Lab Announces Upcoming Presentations in June Investor Conferences

SHANGHAI and SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in J…
Show more

ZAI Lab Frequently Asked Questions

  • When was ZAI Lab founded?

    ZAI Lab was founded in 2013.

  • Who are ZAI Lab key executives?

    ZAI Lab's key executives are Samantha Du, Yongjiang Hei and Harald Reinhart.

  • How many employees does ZAI Lab have?

    ZAI Lab has 1,194 employees.

  • Who are ZAI Lab competitors?

    Competitors of ZAI Lab include EMS Pharma, Livzon Pharmaceutical Group and Cipla.

  • Where are ZAI Lab offices?

    ZAI Lab has offices in Suzhou Shi, Cambridge and Menlo Park.

  • How many offices does ZAI Lab have?

    ZAI Lab has 6 offices.